| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.7M | +39.2% | +22.9% |
| R&D Expense | $56.1M | -5.7% | +3.1% |
| SG&A Expense | $20.3M | +1.9% | +4.3% |
| Operating Income | -$52.4M | +17.2% | +15.6% |
| Net Income | -$61.9M | +12.6% | -3.9% |
| EPS (Basic) | -$1.20 | +13.0% | -2.6% |
| EPS (Diluted) | -$1.20 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $58.8M | -26.1% | +3.9% |
| Short-term Investments | $215.4M | -11.6% | +8.3% |
| Accounts Receivable | $25.3M | +25.5% | +7.4% |
| Current Assets | $332.0M | -11.2% | +5.9% |
| Total Assets | $525.2M | -9.6% | +1.2% |
| Current Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$71.7M | — | — |
| Capital Expenditures | $1.9M | — | — |
| Investing Cash Flow | -$53.4M | — | — |
| Financing Cash Flow | $126.4M | — | — |
| Free Cash Flow | -$73.6M | — | — |
| +13.0% |
| -2.6% |
| $124.6M |
| +4.2% |
| +21.3% |
| Total Liabilities | $363.8M | -1.0% | +67.1% |
| Stockholders' Equity | $161.5M | -24.4% | -46.4% |